Clinical trials: Onabotulinum Toxin A
Transfer Dysphagia, Oropharyngeal Dysphagia
Onabotulinum Toxin A (Botox) in the Treatment of Pharyngo-esophageal Dysphagia
Dysphagia in patients with stroke, multiple sclerosis, parkinsonism or dystonia can occur due to relative hypertonia of the cricopharyngeus muscle. In the resting state, muscle is contracted and relaxes only during deglutition.
- Conditions
- Transfer Dysphagia, Oropharyngeal Dysphagia, Cricopharyngeus Muscle Dysfunction
- Trial name
- NCT04695600
- Testing
- Botulinum Toxin Type A Injection [Botox]
- Where
- India
- Volunteers
- 100 people
- Sponsor
- All India Institute of Medical Sciences
Interstitial Cystitis
Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
The purpose of this research study is to identify the optimal usage of Onabotulinumtoxin A in interstitial cystitis. Onabotulinumtoxin A, more commonly known by the trade name Botox®, is a medication that comes from the bacteria…
- Trial name
- NCT02297100
- Testing
- Onabotulinumtoxin A, injections upper aspect of trigone of urinary bladder, injections on posterior bladder wall excluding the trigone
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Male, Ultrasonography
Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia
To compare safely and efficacy of intraprostatic injection of botulinum toxin A versus ethanol for treatment of benign prostatic hyperplasia (BPH).
- Conditions
- Male, Ultrasonography, Botulinum Toxins, Type A, Injection; Complications, Infection
- Trial name
- NCT03385161
- Testing
- Botulinum toxin A, Ethanol
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Cairo University
Raynaud's Disease
A Two-Part Study of BOTOX® Therapy for Ischemic Digits
Treating patients with Raynaud's phenomenon who have chronic pain and ulcerations is extremely challenging. Published reports and our previous work support our hypothesis that symptomatic patients experience relief of pain and…
- Trial name
- NCT01309802
- Testing
- onabotulinum toxin type-A
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Southern Illinois University
Facial Fine Lines
Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines
The main objective of this study is to assess safety and tolerability of Intradermal (ID) BOTOX in participants with facial fine lines.
- Trial name
- NCT04631588
- Testing
- Botox
- Where
- 5 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Allergan
Overactive Bladder (OAB), Urge Incontinence
Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections
Single-site prospective observational pilot feasibility study of women with overactive bladder/urge urinary incontinence undergoing onabotulinum toxin type A intradetrusor injections in order to achieve the following objectives…
- Trial name
- MICROAB_Pilot (NCT07025044)
- Testing
- onabotulinum toxin type a
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Alexis Dieter
Spinal Cord Injuries, Urinary Bladder, Overactive
Prevention of Bladder Dysfunction in Acute Spinal Cord Injury
This study is a double blind, randomized, placebo controlled trial to explore the effect of early treatment with Onabotulinumtoxin A in patients with acute complete motor spinal cord injury (SCI) on the development of neurogenic…
- Trial name
- BOT-SCI (NCT01698138)
- Testing
- Onabotulinumtoxin A
- Where
- 2 sites in Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Overactive Bladder, Diversity
Diversity in Patients With OAB
An overactive bladder (OAB) is a condition characterized by frequent en nightly voiding, small bladder capacity and the occurrence of sudden urge to void, with or without urinary incontinence.
- Conditions
- Overactive Bladder, Diversity, Onabotulinum Toxin A, Sacral Neuromodulation
- Trial name
- DOAB (NCT05903105)
- Testing
- Questionnaires
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Ghent
Neurogenic Bladder Disorder
Predictive Urodynamic Parameters for The Treatment Efficacy of Onabotulinum A Toxin in Neurogenic Lower Urinary Tract Dysfunction
Purpose: To evaluate urodynamic parameters predicting the treatment efficacy of onabotulinumtoxin A (onaBoNT-A) in patients with neurogenic lower urinary tract dysfunction (NLUTD).
- Trial name
- NCT06485453
- Testing
- Botox 200 UNT Injection
- Volunteers
- 74 people
- Sponsor
- University of Gaziantep
Overactive Bladder
OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER
Overactive bladder is a condition associated with symptoms of feeling the urge to urinate, urinating often, and may or may not be accompanied by leakage of urine.
- Trial name
- NCT01050114
- Testing
- onaBoNT-A, Oxybutynin ER
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Christopher Patrick Smith
Overactive Bladder
Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?
The purpose of this research study is to help determine if 10 injections of Botox ® 100 units is less painful than 20 injections of Botox ® 100 units based on effectiveness in reducing urge incontinence episodes.
- Trial name
- NCT04124939
- Testing
- OnabotulinumtoxinA 100 Units
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Wake Forest University Health Sciences
Overactive Bladder, Overactive Bladder Syndrome
Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections
The purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections.
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency
- Trial name
- NCT06695585
- Testing
- Lidocaine 2% without vessel constrictor
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Louisville
Parkinson's Disease, Neurogenic Bladder
Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
The basic nerve deficit of Parkinson's disease (PD) leads to lower urinary tract symptoms of frequency, urgency and urge urinary incontinence. Lower urinary tract symptoms tend to occur at more advanced stages of PD.
- Conditions
- Parkinson's Disease, Neurogenic Bladder, Urinary Incontinence, Clostridium Botulinum Toxin Adverse Reaction
- Trial name
- NCT01421719
- Testing
- Cystoscopic injection of Botox into the urinary bladder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Chronic Pain, Post-thoracotomy Pain Syndrome
Botulinum Toxin A as Treatment for Chronic Postsurgical Pain Following Lung Cancer Surgery
Chronic postsurgical pain following lung cancer surgery is common with and 20-60 % develop chronic pain which persists more than six months after surgery. Causes and health impact of this pain have been comprehensively studied.
- Conditions
- Chronic Pain, Post-thoracotomy Pain Syndrome, Pain, Neuropathic, Pain, Postoperative
- Trial name
- NCT04585620
- Testing
- Onabotulinum Toxin A, Normal saline
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Allan Vestergaard Danielsen, MD
Neuropathic Pain
Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain
Onabotulinum toxin type A (BoNT-A) is a potent neurotoxin that has been reported to have an effect on afferent (sensory) neurons independent of its action on muscle tone and secretory glands at the periphery.In human studies, the…
- Trial name
- NCT03848143
- Testing
- onabotulinum toxin A
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Isabel Moreno Hay
Intrinsic Aging of Skin, Solar Elastosis
Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study
The objective of the study is to compare the time to onset of Dysport® versus Botox® in the treatment of lateral orbital rhytids ("crow's feet").
- Trial name
- NCT01529788
- Testing
- Right lateral orbital injection of Botox Cosmetic or Dysport, Left lateral orbital injection of Botox Cosmetic or Dysport
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- The Maas Clinic
Spasticity, Focal Dystonia
Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia
This study seeks to compare the use of ultrasound and electrophysiologic techniques to target muscles for the treatment of spasticity and focal dystonia of the limbs.
- Conditions
- Spasticity, Focal Dystonia, Tremor, Limb
- Trial name
- NCT02334683
- Testing
- Electrical stimulation, Ultrasound
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Overactive Bladder
Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB)
Instillation treatment with onabotulinumtoxin A (BOTOX®) in the urinary bladder
- Trial name
- NCT02735499
- Testing
- onabotulinum toxin A
- Where
- Norway
- Volunteers
- 14 people
- Sponsor
- The Hospital of Vestfold
Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS
Benign prostatic hyperplasia (BPH) and its related symptoms are a common condition that affects nearly half of men over age 50 and 90% of men over 80.
- Trial name
- NCT01589263
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- VA Office of Research and Development
Wrinkles
A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles
The purpose of this study is to compare the effectiveness of Botox® (Onabotulinum Toxin A) versus Xeomin® (incobotulinum toxin A) for the treatment of forehead and glabellar (vertical lines between the eyebrows) wrinkles.
- Trial name
- NCT02019004
- Testing
- Onabotulinum Toxin A, Incobotulinum Toxin A
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Northwestern University